Cargando…

Left Atrial Thrombus in Atrial Fibrillation/Flutter Patients in Relation to Anticoagulation Strategy: LATTEE Registry

Background: Atrial fibrillation (AF) and flutter (AFl) increase the risk of thromboembolism. The aim of the study was to assess the prevalence of left atrial thrombus (LAT) in AF/AFl in relation to oral anticoagulation (OAC). Methods: LATTEE (NCT03591627) was a multicenter, prospective, observationa...

Descripción completa

Detalles Bibliográficos
Autores principales: Kapłon-Cieślicka, Agnieszka, Gawałko, Monika, Budnik, Monika, Uziębło-Życzkowska, Beata, Krzesiński, Paweł, Starzyk, Katarzyna, Gorczyca-Głowacka, Iwona, Daniłowicz-Szymanowicz, Ludmiła, Kaufmann, Damian, Wójcik, Maciej, Błaszczyk, Robert, Hiczkiewicz, Jarosław, Łojewska, Katarzyna, Mizia-Stec, Katarzyna, Wybraniec, Maciej T, Kosmalska, Katarzyna, Fijałkowski, Marcin, Szymańska, Anna, Dłużniewski, Mirosław, Haberka, Maciej, Kucio, Michał, Michalski, Błażej, Kupczyńska, Karolina, Tomaszuk-Kazberuk, Anna, Wilk-Śledziewska, Katarzyna, Wachnicka-Truty, Renata, Koziński, Marek, Burchardt, Paweł, Scisło, Piotr, Piątkowski, Radosław, Kochanowski, Janusz, Opolski, Grzegorz, Grabowski, Marcin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9143266/
https://www.ncbi.nlm.nih.gov/pubmed/35628832
http://dx.doi.org/10.3390/jcm11102705
Descripción
Sumario:Background: Atrial fibrillation (AF) and flutter (AFl) increase the risk of thromboembolism. The aim of the study was to assess the prevalence of left atrial thrombus (LAT) in AF/AFl in relation to oral anticoagulation (OAC). Methods: LATTEE (NCT03591627) was a multicenter, prospective, observational study enrolling consecutive patients with AF/AFl referred for transesophageal echocardiography before cardioversion or ablation. Results: Of 3109 patients enrolled, 88% were on chronic, 1.5% on transient OAC and 10% without OAC. Of patients on chronic OAC, 39% received rivaroxaban, 30% dabigatran, 14% apixaban and 18% vitamin K antagonists (VKA). Patients on apixaban were oldest, had the worst renal function and were highest in both bleeding and thromboembolic risk, and more often received reduced doses. Prevalence of LAT was 8.0% (7.3% on chronic OAC vs. 15% without OAC; p < 0.01). In patients on VKA, prevalence of LAT was doubled compared to patients on non-VKA-OACs (NOACs) (13% vs. 6.0%; p < 0.01), even after propensity score weighting (13% vs. 7.5%; p < 0.01). Prevalence of LAT in patients on apixaban was higher (9.8%) than in those on rivaroxaban (5.7%) and dabigatran (4.7%; p < 0.01 for both comparisons), however, not after propensity score weighting. Conclusions: The prevalence of LAT in AF is non-negligible even on chronic OAC. The risk of LAT seems higher on VKA compared to NOAC, and similar between different NOACs.